XNASBIOR
Market cap2mUSD
Dec 24, Last price
0.47USD
1D
-11.37%
1Q
-16.78%
IPO
-96.07%
Name
Biora Therapeutics Inc
Chart & Performance
P/E
—
P/S
531.64
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
71.01%
Rev. gr., 5y
-87.44%
Revenues
4k
-98.69%
Net income
-124m
L+154.18%
CFO
-48m
L-24.71%
Earnings
Mar 24, 2025
Profile
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 4 -98.69% | 305 -75.54% | 1,247 -98.32% | |||
Cost of revenue | 29,838 | 24,956 | 120,521 | |||
Unusual Expense (Income) | ||||||
NOPBT | (29,834) | (24,651) | (119,274) | |||
NOPBT Margin | ||||||
Operating Taxes | (90) | (420) | (119) | |||
Tax Rate | ||||||
NOPAT | (29,744) | (24,231) | (119,155) | |||
Net income | (124,115) 154.18% | (48,830) -72.65% | (178,521) -7.28% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 18,137 | 12,528 | 46,776 | |||
BB yield | -85.17% | -49.84% | -581.90% | |||
| Debt | ||||||
Debt current | 2,872 | 893 | 12 | |||
Long-term debt | 46,268 | 129,305 | 126,404 | |||
Deferred revenue | ||||||
Other long-term liabilities | 25,110 | 4,696 | 5,814 | |||
Net debt | 30,929 | 93,712 | 38,019 | |||
| Cash flow | ||||||
Cash from operating activities | (48,499) | (64,417) | (167,486) | |||
CAPEX | (103) | (792) | (855) | |||
Cash from investing activities | 2,443 | (792) | (1,242) | |||
Cash from financing activities | 30,781 | 7,298 | 165,049 | |||
FCF | 11,651 | (23,355) | (105,325) | |||
| Balance | ||||||
Cash | 15,211 | 30,486 | 88,397 | |||
Long term investments | 3,000 | 6,000 | ||||
Excess cash | 18,211 | 36,471 | 88,335 | |||
Stockholders' equity | (950,933) | (826,835) | (788,540) | |||
Invested Capital | 922,048 | 857,948 | 835,782 | |||
ROIC | ||||||
ROCE | 103.29% | |||||
| EV | ||||||
Common stock shares outstanding | 15,773 | 7,635 | 3,846 | |||
Price | 1.35 -59.00% | 3.29 57.54% | 2.09 -60.64% | |||
Market cap | 21,294 -15.29% | 25,139 212.73% | 8,039 -32.14% | |||
EV | 52,223 | 118,851 | 46,058 | |||
EBITDA | (29,279) | (23,744) | (117,837) | |||
EV/EBITDA | ||||||
Interest | 9,815 | 10,990 | 12,636 | |||
Interest/NOPBT | ||||||